News Archive
17
February 2010
Fourth Quarter Report 2009
Clavis Pharma delivers strong performance in the last quarter of 2009. CP-4126 development accelerated through partnership. Financial position further strengthened.
Fourth Quarter Report 2009
Clavis Pharma delivers strong performance in the last quarter of 2009. CP-4126 development accelerated through partnership. Financial position further strengthened.
8 January 2010
Clavis Pharma appoints Olav Hellebø as Chief Executive Officer
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announced today that it has appointed Olav Hellebø as its new Chief Executive Officer (CEO). Mr Hellebø, who joins Clavis Pharma from UCB Pharma, has significant senior management experience in the pharmaceutical industry and has been appointed to lead the Company as it embarks on a new phase of international clinical and commercial development. Mr Hellebø will take up his position on 1st February 2010.
Clavis Pharma appoints Olav Hellebø as Chief Executive Officer
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announced today that it has appointed Olav Hellebø as its new Chief Executive Officer (CEO). Mr Hellebø, who joins Clavis Pharma from UCB Pharma, has significant senior management experience in the pharmaceutical industry and has been appointed to lead the Company as it embarks on a new phase of international clinical and commercial development. Mr Hellebø will take up his position on 1st February 2010.
8 January 2010
Clavis Pharma receives US Orphan Drug Designation for CP-4126 to treat pancreatic cancer
Clavis Pharma (OSE: CLAVIS); the Norwegian cancer drug development company, announced today that the US Food & Drug Administration (FDA) has granted orphan drug designation to CP-4126 for the treatment of pancreatic cancer. The designation follows the equivalent designation given by the European Commission in October last year.
Clavis Pharma receives US Orphan Drug Designation for CP-4126 to treat pancreatic cancer
Clavis Pharma (OSE: CLAVIS); the Norwegian cancer drug development company, announced today that the US Food & Drug Administration (FDA) has granted orphan drug designation to CP-4126 for the treatment of pancreatic cancer. The designation follows the equivalent designation given by the European Commission in October last year.
21 December 2009
Clavis Pharma ASA receives NOK 20 million Loan from Innovation Norway to Support the Phase III Programme of Elacytarabine in Acute Myeloid Leukaemia
Clavis Pharma ASA (OSE: CLAVIS) announced today that it has received an unsecured loan of NOK 20 million (USD 3.2 million) from Innovation Norway to support the Phase III clinical programme with Elacytarabine in patients with late-stage acute myeloid leukaemia (AML).
Clavis Pharma ASA receives NOK 20 million Loan from Innovation Norway to Support the Phase III Programme of Elacytarabine in Acute Myeloid Leukaemia
Clavis Pharma ASA (OSE: CLAVIS) announced today that it has received an unsecured loan of NOK 20 million (USD 3.2 million) from Innovation Norway to support the Phase III clinical programme with Elacytarabine in patients with late-stage acute myeloid leukaemia (AML).
7 December 2009
Positive Phase II clinical data for Clavis Pharma's Elacytarabine presented at ASH Annual Meeting
Clavis Pharma ASA (OSE: CLAVIS) announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia (AML) was presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, LA, USA. Elacytarabine is a novel, patented, lipid-conjugated form of the anti-cancer drug cytarabine (Ara-C) that has the potential to improve treatment outcomes in patients with AML and other haematological malignancies (leukaemias). Elacytarabine has Orphan Drug Designation in the USA and Europe for the treatment of AML.
Positive Phase II clinical data for Clavis Pharma's Elacytarabine presented at ASH Annual Meeting
Clavis Pharma ASA (OSE: CLAVIS) announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia (AML) was presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, LA, USA. Elacytarabine is a novel, patented, lipid-conjugated form of the anti-cancer drug cytarabine (Ara-C) that has the potential to improve treatment outcomes in patients with AML and other haematological malignancies (leukaemias). Elacytarabine has Orphan Drug Designation in the USA and Europe for the treatment of AML.
4 December 2009
Positive Phase II clinical data for Clavis Pharma’s elacytarabine to be presented at ASH Annual Meeting 2009
Clavis Pharma ASA (OSE: CLAVIS) announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia (AML) will be presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, LA, USA, tomorrow at at 5:30 PM - 7:30 PM (PST) in Hall E (Ernest N. Morial Convention Center).
Positive Phase II clinical data for Clavis Pharma’s elacytarabine to be presented at ASH Annual Meeting 2009
Clavis Pharma ASA (OSE: CLAVIS) announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia (AML) will be presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, LA, USA, tomorrow at at 5:30 PM - 7:30 PM (PST) in Hall E (Ernest N. Morial Convention Center).
24 November 2009
Clavis Pharma and Clovis Oncology Sign $380 Million Partnership for the Development and Commercialisation of Anti-Cancer Agent CP-4126
CP-4126 is a novel, lipid-conjugated form of gemcitabine designed by Clavis Pharma to improve treatment outcomes in patients with pancreatic and other solid tumours. - Clavis Pharma to receive up to $380 million in staged payments, including a $15 million signing fee, and tiered double-digit royalties on sales. -Clovis Oncology fully responsible for the clinical development of CP-4126. -Clovis Oncology to commercialise CP-4126 in the United States, Europe, Canada, Central and South America. -Clavis Pharma retains an option to co-promote and share profits in Europe. -Companies to collaborate on development of a companion diagnostic test to identify patients likely to benefit most from CP-4126 treatment.
Clavis Pharma and Clovis Oncology Sign $380 Million Partnership for the Development and Commercialisation of Anti-Cancer Agent CP-4126
CP-4126 is a novel, lipid-conjugated form of gemcitabine designed by Clavis Pharma to improve treatment outcomes in patients with pancreatic and other solid tumours. - Clavis Pharma to receive up to $380 million in staged payments, including a $15 million signing fee, and tiered double-digit royalties on sales. -Clovis Oncology fully responsible for the clinical development of CP-4126. -Clovis Oncology to commercialise CP-4126 in the United States, Europe, Canada, Central and South America. -Clavis Pharma retains an option to co-promote and share profits in Europe. -Companies to collaborate on development of a companion diagnostic test to identify patients likely to benefit most from CP-4126 treatment.
24 November 2009
Invitation to Meeting and Conference Call for Clavis Pharma’s $380 Million Partnering Agreement
Clavis Pharma ASA (OSE: CLAVIS), the clinical stage oncology focused pharmaceutical company, announced today a $380 million agreement for the further development and commercialisation of its drug candidate, CP-4126, currently in Phase II development in pancreatic cancer. A meeting for investors, analysts and press will take place in Oslo at 10.00 CET today, 24 November 2009 at Hotel Continental, Stortingsgaten 24, Oslo Norway.
Invitation to Meeting and Conference Call for Clavis Pharma’s $380 Million Partnering Agreement
Clavis Pharma ASA (OSE: CLAVIS), the clinical stage oncology focused pharmaceutical company, announced today a $380 million agreement for the further development and commercialisation of its drug candidate, CP-4126, currently in Phase II development in pancreatic cancer. A meeting for investors, analysts and press will take place in Oslo at 10.00 CET today, 24 November 2009 at Hotel Continental, Stortingsgaten 24, Oslo Norway.
30 October 2009
The European Commission grants Orphan Drug Designation for Intravenous CP-4126 for the Treatment of Pancreatic Cancer
Clavis Pharma ASA (OSE: CLAVIS); the clinical stage oncology focused pharmaceutical company, announces today that the European Commission has granted Orphan Drug Designation (Orphan Medicinal Product) for Intravenous CP-4126 for the treatment of pancreatic cancer. The designation follows the recommendation given by the European Medicines Agency (EMEA) in September this year.
The European Commission grants Orphan Drug Designation for Intravenous CP-4126 for the Treatment of Pancreatic Cancer
Clavis Pharma ASA (OSE: CLAVIS); the clinical stage oncology focused pharmaceutical company, announces today that the European Commission has granted Orphan Drug Designation (Orphan Medicinal Product) for Intravenous CP-4126 for the treatment of pancreatic cancer. The designation follows the recommendation given by the European Medicines Agency (EMEA) in September this year.
22 October 2009
Third Quarter Report 2009
Clavis Pharma ASA (OSE: CLAVIS); the clinical stage oncology focused pharmaceutical company, announces today its results for the third quarter 2009. Following positive Phase II results for elacytarabine in acute myeloid leukaemia (AML) announced in June, the Company continues to make progress with the further development of this new potential anti-cancer drug.
Third Quarter Report 2009
Clavis Pharma ASA (OSE: CLAVIS); the clinical stage oncology focused pharmaceutical company, announces today its results for the third quarter 2009. Following positive Phase II results for elacytarabine in acute myeloid leukaemia (AML) announced in June, the Company continues to make progress with the further development of this new potential anti-cancer drug.